Summit Therapeutics Inc. Interest Expense
Summit Therapeutics Inc. (SMMT) reported Interest Expense of $8.33 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2023-05-11
- Summit Therapeutics Inc. interest expense for the quarter ending 2023-03-31 was $8.33M, a 5378.29% increase year-over-year.
- Summit Therapeutics Inc. interest expense for the quarter ending 2022-12-31 was $2.90M.
- Summit Therapeutics Inc. interest expense for the quarter ending 2022-09-30 was $692.00K.
- Summit Therapeutics Inc. interest expense for the quarter ending 2022-06-30 was $653.00K, a 202.31% increase year-over-year.
- Summit Therapeutics Inc. interest expense for fiscal 2022 was $4.40M, a 1718.60% increase from fiscal 2021.
- Summit Therapeutics Inc. interest expense for fiscal 2021 was $242.00K, a 5.10% decline from fiscal 2020.
- Summit Therapeutics Inc. interest expense for fiscal 2020 was $255.00K.
- Summit Therapeutics Inc. interest expense for fiscal 2019 was $620.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 11 month | Interest Expense 11 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-03-31 | $8.33M 10-Q · filed 2023-05-11 | $11.23M derived: sum of 2 quarters · filed 2023-05-11 | $11.92M derived: sum of 3 quarters · filed 2023-05-11 | $12.58M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2022-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.60M derived: sum of 2 quarters · filed 2023-03-09 | $4.25M derived: sum of 3 quarters · filed 2023-03-09 | $4.40M 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $692.00K 10-Q · filed 2022-11-09 | $1.34M derived: sum of 2 quarters · filed 2022-11-09 | $1.50M 10-Q · filed 2022-11-09 | $1.50M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2022-06-30 | $653.00K 10-Q · filed 2022-08-11 | $805.00K 10-Q · filed 2022-08-11 | $803.00K derived: sum of 3 quarters · filed 2023-05-11 | $803.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2022-03-31 | $152.00K 10-Q · filed 2023-05-11 | $150.00K derived: sum of 2 quarters · filed 2023-05-11 | $150.00K derived: sum of 3 quarters · filed 2023-05-11 | $366.00K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$2.00K derived: sum of 2 quarters · filed 2023-03-09 | $214.00K derived: sum of 3 quarters · filed 2023-03-09 | $242.00K 10-K · filed 2023-03-09 | $281.00K 10-K · filed 2022-03-17 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $216.00K derived: sum of 2 quarters · filed 2022-11-09 | $244.00K 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $216.00K 10-Q · filed 2022-08-11 | $242.00K 10-Q · filed 2022-08-11 | |||||
| 2020-12-31 | $255.00K 10-K/A · filed 2022-12-21 | ||||||
| 2020-06-30 | $120.00K 8-K · filed 2020-09-29 | ||||||
| 2019-12-31 | $291.00K 10-K · filed 2021-03-31 | $286.00K 8-K · filed 2020-09-29 | |||||
| 2019-06-30 | $156.00K 8-K · filed 2020-09-29 | ||||||
| 2019-01-31 | $620.00K 10-K · filed 2021-03-31 | $615.00K 8-K · filed 2020-09-29 | |||||
| 2018-01-31 | $1.54M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |